Why Is Boston Scientific (BSX) Down 13% Since Last Earnings Report?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
More News
ISRG's SP Platform: Early-Stage Growth or Next TAM Expansion Driver?
ISRG's SP platform sees Q1 2026 procedures jump 68%, with new approvals and tools raising a key question: TAM expansion or procedure shift?
Boston Scientific Corporation (BSX) Fell Due to Weak Results
Boston Scientific Corporation (BSX) Fell Due to Weak Results...
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum
ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans.
Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target
Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target...
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?
According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Company News for May 19, 2026
Companies In The Article Are:REGN,D,NEE,STX and BSX
FRACTURE IDE trial of the Boston Scientific SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
FRACTURE IDE trial of the Boston Scientific SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints FRACTURE IDE trial of the Boston Scientific...
Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years
read more...
Boston Scientific Targets Growing Aortic Stenosis Market With $1.5 Billion Deal
Boston Scientific invested $1.5 billion in MiRus and secured an option to acquire its investigational SIEGEL TAVR system.read more...